Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 6,010,000 shares, a decrease of 7.5% from the November 15th total of 6,500,000 shares. Based on an average trading volume of 713,200 shares, the short-interest ratio is presently 8.4 days.

Crinetics Pharmaceuticals Stock Up 1.8 %

Crinetics Pharmaceuticals stock traded up $0.97 during trading hours on Monday, hitting $54.63. 1,188,997 shares of the company traded hands, compared to its average volume of 772,097. Crinetics Pharmaceuticals has a 1-year low of $32.92 and a 1-year high of $62.53. The firm has a market cap of $5.07 billion, a P/E ratio of -14.54 and a beta of 0.60. The firm's 50-day simple moving average is $56.85 and its two-hundred day simple moving average is $52.45.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.05). During the same quarter last year, the business posted ($1.01) EPS. On average, equities research analysts predict that Crinetics Pharmaceuticals will post -3.75 earnings per share for the current year.

Insider Activity at Crinetics Pharmaceuticals

In related news, insider Dana Pizzuti sold 14,375 shares of the business's stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total transaction of $785,306.25. Following the completion of the sale, the insider now owns 28,507 shares of the company's stock, valued at $1,557,337.41. This represents a 33.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Marc Wilson sold 25,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $51.11, for a total transaction of $1,277,750.00. Following the sale, the chief financial officer now owns 111,092 shares in the company, valued at approximately $5,677,912.12. This trade represents a 18.37 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,876 shares of company stock valued at $2,091,373. Corporate insiders own 6.00% of the company's stock.

Institutional Trading of Crinetics Pharmaceuticals

Several institutional investors have recently modified their holdings of CRNX. Driehaus Capital Management LLC raised its position in Crinetics Pharmaceuticals by 17.0% in the second quarter. Driehaus Capital Management LLC now owns 6,112,173 shares of the company's stock worth $273,764,000 after acquiring an additional 885,876 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Crinetics Pharmaceuticals by 0.5% in the 3rd quarter. Jennison Associates LLC now owns 2,793,614 shares of the company's stock worth $142,754,000 after purchasing an additional 13,470 shares in the last quarter. First Turn Management LLC acquired a new stake in Crinetics Pharmaceuticals during the second quarter valued at approximately $16,541,000. Fisher Asset Management LLC boosted its holdings in Crinetics Pharmaceuticals by 8.4% during the third quarter. Fisher Asset Management LLC now owns 482,099 shares of the company's stock worth $24,635,000 after buying an additional 37,429 shares in the last quarter. Finally, Nicholas Investment Partners LP bought a new stake in Crinetics Pharmaceuticals during the second quarter worth approximately $2,374,000. Institutional investors and hedge funds own 98.51% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on CRNX shares. JMP Securities reiterated a "market outperform" rating and set a $87.00 price target on shares of Crinetics Pharmaceuticals in a research report on Monday. HC Wainwright increased their target price on Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $90.00 price target on shares of Crinetics Pharmaceuticals in a report on Monday, September 16th. Finally, Citigroup increased their price objective on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Crinetics Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $70.82.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.